These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33807839)

  • 1. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.
    Funk CD; Laferrière C; Ardakani A
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
    Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
    Front Immunol; 2021; 12():771242. PubMed ID: 34880867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
    Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
    Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of COVID-19 vaccines: From clinical trials to real life.
    Deplanque D; Launay O
    Therapie; 2021; 76(4):277-283. PubMed ID: 34049688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 vaccines: a triumph of science and collaboration.
    Golob JL; Lugogo N; Lauring AS; Lok AS
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33822773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines.
    Ndwandwe D; Wiysonge CS
    Curr Opin Immunol; 2021 Aug; 71():111-116. PubMed ID: 34330017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
    Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
    Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in virus-like particle-based SARS-CoV-2 vaccines.
    Hao X; Yuan F; Yao X
    Front Cell Infect Microbiol; 2024; 14():1406091. PubMed ID: 38988812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines.
    Hofman K; Shenoy GN; Chak V; Balu-Iyer SV
    Immunol Invest; 2021 Oct; 50(7):743-779. PubMed ID: 33929280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.